View in EDS

Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity.

Saved in:

Bibliographic Details
Title:	Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity.
Authors:	Jokic V; Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia., Savic-Vujovic K; Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia., Spasic J; Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia., Stanic N; Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia., Marinkovic M; Clinic for Radiation Oncology and Diagnostics, Department of Radiation Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia., Radosavljevic D; Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia., Cavic M; Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Source:	Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2021 Jun; Vol. 21 (6), pp. 673-679. Date of Electronic Publication: 2021 Mar 01.
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1744-8328
DOI:	10.1080/14737140.2021.1893694